Current treatments for CNS disorders act broadly across the brain, dampening only some symptoms without addressing the underlying circuit dysfunction and at the cost of side effects, abuse risk, or complex clinical delivery.

Our approach is different. We develop precision neuromodulators designed to act where dysfunction originates—within specific brain circuits. By modulating AMPA receptors and leveraging TARP biology, our small molecules are designed to target and restore activity in defined regions, aiming to correct dysfunction and re-establish healthy circuit plasticity while sparing the rest of the brain.